News | October 23, 2006

Surgery Found to be Less Risky than Stents

When it comes to opening blocked carotid arteries, surgery may be less risky than stents according to a study by French doctors including Jean-Louis Mas, M.D., of the Hospitaux Sainte-Anne in Paris.

The carotid arteries run through the neck, taking blood to the brain. They can become narrowed from plaque buildup, making strokes more likely. Mas' team found that patients who got surgery instead of stents to open the carotid arteries were less likely to die or have strokes in the first six months after their procedure.

The study appears in The New England Journal of Medicine.

Mas' team studied 527 French patients who had a carotid artery at least 60 percent more narrow than normal. The patients had all experienced a non-disabling stroke, or "mini-stroke," because of the blockage. The researchers randomly assigned patients to get carotid artery surgery or stents.

Over the next six months, 6 percent of the surgery group died or had a stroke, compared with about 11 percent of the stent group.

They stopped the experiment early due to those findings and called for larger, longer studies to check their results.


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now